Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq of iPSC-ECs treated with and without uremic toxin mixtures (UT-H).

ABSTRACT: Three healthy iPSC lines were differentiated into ECs. iPSC-ECs were then treated with and without UT-H for 24 hours.

ORGANISM(S): Homo sapiens

PROVIDER: GSE155969 | GEO | 2021/02/02

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

RNA-seq of iPSC-ECs treated with and without uremic toxin mixtures (UT-H).

Project description:RNA-seq of iPSC-ECs treated with and without uremic toxin mixtures (UT-H).

| PRJNA656243 | ENA

lncRNA Array of iPSC-ECs treated with and without e-cigarette extraction

Project description:Four healthy iPSC lines were differentiated into ECs. iPSC-ECs were then treated with and without e-cigarette extraction for 24 hours.

2024-10-16 | GSE186227 | GEO

RNA-seq of iPSC-ECs treated e-cig liquids with and without nicotine

Project description:Two healthy iPSC lines (78 and 273) were differentiated into ECs. iPSC-ECs were then treated with e-cig liquids RY4 (RY) or Marcado (MAR) with 18mg/ml of nicotine (18) and without nicotine (0).

2020-08-11 | GSE125217 | GEO

RNA-seq of iPSC-ECs treated under normoglycemic and hyperglycemic conditions with and without MDL-28170 treatment

Project description:Two healthy iPSC lines were differentiated into ECs. iPSC-ECs were then treated under normoglycemic (5.5mM glucose) or hyperglycemic (33mM glucose) conditions with and without MDL-28170 (2.5 uM) for 72 hours.

2019-02-15 | GSE123699 | GEO

lncRNA Array of iPSC-ECs treated with and without e-cigarette extraction

Project description:lncRNA Array of iPSC-ECs treated with and without e-cigarette extraction

| PRJNA773042 | ENA

Differentially expressed vascular development genes for iPSC-ECs from CDI

Project description:Here we report genes upregulated for iPSC-ECs cultured in PEG hydrogels relative to control cells on tissue culture polystyrene (TCP) surfaces included adhesion, matrix remodeling, and Notch signaling pathway genes relevant to in vivo vascular development.

2016-03-08 | GSE78925 | GEO

RNA-seq of iPSC-ECs treated e-cig liquids with and without nicotine

Project description:RNA-seq of iPSC-ECs treated e-cig liquids with and without nicotine

| PRJNA515535 | ENA

Identification of the UT-A1 Urea Channel Interactome

Project description:The urea channel Slc14a2 (or UT-A1) mediates vasopressin-regulated urea transport across the inner medullary collecting duct (IMCD). Previously, UT-A1 was found to present in a high molecular weight complex, suggesting UT-A1 is involved in certain protein-protein interactions. The present study sought to identify the proteins that interact with UT-A1 in this complex for a better understanding of how UT-A1 is regulated. Rat IMCD suspensions were treated with or without V2 receptor agonist, dDAVP, followed by in-cell crosslinking using BSOCOES and detergent solubilization. Immunoprecipitation using Dynabeads coated with UT-A1 specific antibody successfully pulled down the UT-A1 proteins. In-gel digestion protocol was carried out to prepare samples for liquid chromatographic mass spectrometry analysis of tryptic peptides using a Velos-Orbitrap mass spectrometer. The peptides passing stringent spectral quality thresholds were quantified (label-free) to identify those with (UTA-1 antibody/preimmune IgG) >4. A total of 128 UT-A1 interacting proteins were identified. Gene Ontology analysis maps the distribution of these proteins throughout major cell compartments: endoplasmic reticulum, Golgi, endosomes, cytosol and plasma membrane. Among them are four protein kinases (Cdc42bpb, Phkb, Camk2d, Mtor) that play roles in vasopressin-regulated phosphorylation of UT-A1. Non-label quantification was also performed to determine the stoichiometry of UT-A3 with UT-A1, the result does not support an oligomeric complex formation of UT-A1/A3. In conclusion, we have provided a refined list of UT-A1 binding proteins which can be useful for further analysis of the vasopressin signaling pathway in regulation of UT-A1 in IMCD.

2019-11-08 | PXD003496 | Pride

Effect of Network-Correcting Molecules on NOTCH1 (N1)-Haploinsufficient Human Induced Pluripotent Stem Cell (iPSC)-Derived Endothelial Cells (ECs)

Project description:Discovery of small molecules that correct gene networks dysregulated in human disease may allow identification of therapies that treat disease at its fundamental basis by leveraging mechanism-based data. Here, we report the first broad gene network-based drug screen, which led to discovery of a drug candidate that effectively treats aortic valve disease in an animal model. We previously reported haploinsufficiency of NOTCH1 (N1) as a genetic cause of human aortic valve thickening and calcification, the third most common form of heart disease, and described the resulting gene network dysregulation in human induced pluripotent stem cell (iPSC)-derived endothelial cells (ECs). We exposed isogenic N1+/+ or N1+/– iPSC-derived ECs to each of 1595 small molecules or control and developed a machine learning approach that accurately distinguished WT or N1-haploinsufficient cells based on expression of 119 genes assayed by targeted RNA-sequencing. 9 small molecules corrected the gene network of N1+/– ECs sufficiently to be classified as WT. Among hits tested in vivo, the estrogen receptor-related alpha inverse agonist XCT790 significantly reduced aortic valve thickening, calcification, and stenosis in N1-haploinsufficient mice with shortened telomeres, which model the range of age-dependent cardiac disease observed in humans. This strategy, made feasible by human iPSC technology, next generation sequencing approaches, and machine learning, may represent a more effective path for drug discovery compared to conventional screening approaches.

2021-01-01 | GSE125299 | GEO

RNA-seq of iPSC-ECs treated under normoglycemic and hyperglycemic conditions with and without MDL-28170 treatment

Project description:RNA-seq of iPSC-ECs treated under normoglycemic and hyperglycemic conditions with and without MDL-28170 treatment

| PRJNA509626 | ENA